Unfortunately, we do not have data on prescription of new treatments which have been shown to reduce cardiovascular morbidity and mortality in patients with CHF and rEF, such as the combination sacubitril/valsartan or sodium-glucose cotransporter 2 (SGLT2) inhibitors. The gene discussed is SLC5A2; the disease is congestive heart failure.